Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients.

[1]  C. Ramana,et al.  Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma , 2020, JCO precision oncology.

[2]  E. Hsueh,et al.  Prospective validation of the prognostic 31‐gene expression profiling test in primary cutaneous melanoma , 2019, Cancer medicine.

[3]  J. Wolchok,et al.  Immunotherapy of Melanoma: Facts and Hopes , 2019, Clinical Cancer Research.

[4]  C. Morrison,et al.  Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma , 2019, Clinical Cancer Research.

[5]  D. Schadendorf,et al.  Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? , 2018, The Lancet. Oncology.

[6]  D. Brodland,et al.  Estimation of Prognosis in Invasive Cutaneous Melanoma: An Independent Study of the Accuracy of a Gene Expression Profile Test , 2018, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[7]  G. Argenziano,et al.  It is finally time for adjuvant therapy in melanoma. , 2018, Cancer treatment reviews.

[8]  G. Hospers,et al.  Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands , 2018, Anti-cancer drugs.

[9]  C. Berking,et al.  A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging , 2018, JNCI cancer spectrum.

[10]  P. Soares,et al.  Melanoma treatment in review , 2018, ImmunoTargets and therapy.

[11]  A. Ribas,et al.  The new era of adjuvant therapies for melanoma , 2018, Nature Reviews Clinical Oncology.

[12]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[13]  K. Covington,et al.  Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients , 2018, Diagnostic Pathology.

[14]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[15]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[16]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[17]  M. Weinstock,et al.  Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992‐2013 , 2017, Journal of the American Academy of Dermatology.

[18]  J. Hansson,et al.  Epidemiology of cutaneous melanoma in Sweden—Stage‐specific survival and rate of recurrence , 2016, International journal of cancer.

[19]  P. Specenier.  Nivolumab in melanoma , 2016, Expert review of anticancer therapy.

[20]  P. Mazzanti,et al.  Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. , 2016, Cancer treatment reviews.

[21]  M. Gönül,et al.  Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature , 2016, Dermatology research and practice.

[22]  J. Wouters,et al.  Prognostic and predictive biomarkers in melanoma: an update , 2016, Expert review of molecular diagnostics.

[23]  P. Baade,et al.  More people die from thin melanomas (⩽1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. , 2015, The Journal of investigative dermatology.

[24]  H. Storm,et al.  Incidence and survival in patients with cutaneous melanoma by morphology, anatomical site and TNM stage: a Danish Population-based Register Study 1989-2011. , 2015, Cancer epidemiology.

[25]  Robert W Cook,et al.  Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma , 2015, Clinical Cancer Research.

[26]  L. D. Hall,et al.  Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. , 2014, The Journal of investigative dermatology.

[27]  T. Gambichler,et al.  Clinical characteristics and survival data of melanoma patients with nevus cell aggregates within sentinel lymph nodes. , 2013, American journal of clinical pathology.

[28]  D. Schadendorf,et al.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.

[29]  D. Schadendorf,et al.  BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. , 2014, Chinese clinical oncology.